{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:04:42Z","timestamp":1790629482760,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":89,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.07.029","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:52:54Z","timestamp":1785513174000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytokine Release Syndrome and Immune Effector Cell\u2013Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data"],"prefix":"10.1016","author":[{"given":"Matthew J.","family":"Frigault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9629-1891","authenticated-orcid":false,"given":"Theresa","family":"Amoloja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valkal","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jtct.2026.07.029_bib0001","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.029_bib0002","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.029_bib0003","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.029_bib0004","series-title":"Full Prescribing Information","year":"2025"},{"key":"10.1016\/j.jtct.2026.07.029_bib0005","series-title":"Full Prescribing Information","year":"2026"},{"key":"10.1016\/j.jtct.2026.07.029_bib0006","series-title":"Full Prescribing Information","year":"2026"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.029_bib0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jtct.2026.07.029_bib0008","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.029_bib0009","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.07.029_bib0010","series-title":"Full Prescribing Information","year":"2024"},{"key":"10.1016\/j.jtct.2026.07.029_bib0011","series-title":"Full Prescribing Information","year":"2026"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.029_bib0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.029_bib0013","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.029_bib0014","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","article-title":"Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.029_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.029_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.029_bib0017","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"35","key":"10.1016\/j.jtct.2026.07.029_bib0018","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2026.07.029_bib0019","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.029_bib0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.clml.2022.05.004","article-title":"Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"22","author":"Jacobs","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.029_bib0021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00432-025-06249-z","article-title":"Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"151","author":"Schleifenbaum","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.029_bib0022","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtct.2026.07.029_bib0023","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Management of Immunotherapy-Related Toxicities, Version 2.2024. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed November 4, 2024."},{"key":"10.1016\/j.jtct.2026.07.029_bib0024","series-title":"Full Prescribing Information","year":"2022"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.029_bib0025","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.029_bib0026","unstructured":"NIH US National Library of Medicine. Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy. Available at:https:\/\/clinicaltrials.gov\/study\/NCT04359784. Accessed July 28, 2025."},{"key":"10.1016\/j.jtct.2026.07.029_bib0027","unstructured":"NIH US National Library of Medicine. A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04150913. Accessed July 28, 2025."},{"key":"10.1016\/j.jtct.2026.07.029_bib0028","unstructured":"NIH US National Library of Medicine. A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04148430. Accessed July 28, 2025."},{"key":"10.1016\/j.jtct.2026.07.029_bib0029","unstructured":"NIH US National Library of Medicine. A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04071366?term=NCT04071366&rank=1. Accessed July 28, 2025."},{"key":"10.1016\/j.jtct.2026.07.029_bib0030","unstructured":"NIH US National Library of Medicine. Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy. Available at:https:\/\/clinicaltrials.gov\/study\/NCT05044039?term=NCT05044039&rank=1. Accessed July 28, 2025."},{"key":"10.1016\/j.jtct.2026.07.029_bib0031","unstructured":"NIH US National Library of Medicine. Emapalumab Prevention of CAR-T Cell Associated Toxicities. Available at:https:\/\/clinicaltrials.gov\/study\/NCT06550141?term=NCT06550141%20&rank=1#study-plan. Accessed July 28, 2025."},{"issue":"9","key":"10.1016\/j.jtct.2026.07.029_bib0032","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","article-title":"Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma","volume":"9","author":"Frigault","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.029_bib0033","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2024026586","article-title":"Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study","volume":"146","author":"Frigault","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.029_bib0034","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.029_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-23-0228","article-title":"Emerging strategies for the prevention of immune toxicities associated with T cell-engaging cancer therapies","volume":"5","author":"Kowalski","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"26","key":"10.1016\/j.jtct.2026.07.029_bib0036","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2026.07.029_bib0037","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.07.029_bib0038","unstructured":"Center for International Blood and Marrow Transplant Research\u00ae. Lymphoma Response Criteria. Available at:https:\/\/www.manula.com\/manuals\/cibmtr\/fim\/1\/en\/topic\/lymphoma-response-criteria. Accessed July 22, 2025."},{"issue":"27","key":"10.1016\/j.jtct.2026.07.029_bib0039","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.029_bib0040","unstructured":"Center for International Blood and Marrow Transplant Research\u00ae. CIBMTR\u00ae 2024 Annual Report. Available at:https:\/\/cibmtr.org\/Files\/Administrative-Reports\/Annual-Reports\/2024-Annual-Report-DIGITAL.pdf. Accessed July 21, 2025."},{"key":"10.1016\/j.jtct.2026.07.029_bib0041","unstructured":"Center for International Blood and Marrow Transplant Research\u00ae. Protocols & Consent Forms. Available at: https:\/\/cibmtr.org\/CIBMTR\/Data-Operations\/Protocols-Consent-Forms. Accessed July 28, 2025."},{"issue":"1","key":"10.1016\/j.jtct.2026.07.029_bib0042","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.029_bib0043","first-page":"581.e581","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.029_bib0044","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.029_bib0045","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.029_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"issue":"20","key":"10.1016\/j.jtct.2026.07.029_bib0047","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.jtct.2026.07.029_bib0048","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.07.029_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104969","article-title":"Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis","volume":"216","author":"Chen","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.029_bib0050","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.029_bib0051","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/bloodadvances.2025019115","article-title":"Real-world outcomes and toxicities of CAR-T in relapsed\/refractory follicular lymphoma: a multicenter cohort study","volume":"10","author":"Sharp","year":"2026","journal-title":"Blood Adv"},{"issue":"10299","key":"10.1016\/j.jtct.2026.07.029_bib0052","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.029_bib0053","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.07.029_bib0054","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2023-183002","article-title":"Real world experience with a ZUMA -1 cohort 4 adopted approach to CRS and ICANS in CAR-T recipients","volume":"142","author":"Sainatham","year":"2023","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:32:22Z","timestamp":1790627542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"alternative-id":["S2666636726005919"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.029","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine Release Syndrome and Immune Effector Cell\u2013Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}